The fluoxetine market size has grown steadily in recent years. It will grow from $1.03 billion in 2025 to $1.08 billion in 2026 at a compound annual growth rate (CAGR) of 4.7%. The growth in the historic period can be attributed to high prevalence of depressive disorders, clinical effectiveness of SSRIs, availability of generic formulations, increased psychiatric consultations, improved diagnosis of mental health conditions.
The fluoxetine market size is expected to see steady growth in the next few years. It will grow to $1.27 billion in 2030 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to growth in mental health treatment access, expansion of telepsychiatry services, rising stress-related disorders, increased use in pediatric and geriatric care, innovation in antidepressant therapy management. Major trends in the forecast period include rising use of SSRIs in mental health treatment, increased prescription for depression and anxiety disorders, growing adoption of generic fluoxetine, expansion of mental health awareness programs, preference for oral antidepressant therapies.
The rising prevalence of mental health disorders is expected to drive growth in the fluoxetine market. Mental health disorders include a wide range of conditions that impact cognitive, emotional, and behavioral functioning, often causing distress or impairments in daily life. Their increase is influenced by factors such as societal pressures, economic stress, lifestyle changes, and greater awareness and diagnosis. Fluoxetine is used to manage these disorders as it helps alleviate symptoms by increasing serotonin levels in the brain, a key neurotransmitter in mood regulation. For example, in August 2024, the Substance Abuse and Mental Health Services Administration (SAMHSA), a U.S.-based government agency, reported that nearly 25 percent of adults experienced any mental illness (AMI) in 2023, with about 17.1 percent meeting criteria for substance use disorder (SUD). Therefore, the rising prevalence of mental health disorders is boosting the fluoxetine market.
The growth in healthcare expenditure is also expected to support the expansion of the fluoxetine market. Rising healthcare costs are driven by factors such as the adoption of advanced medical technologies, aging populations, and the prevalence of chronic diseases. Higher healthcare spending improves the availability and affordability of medications like fluoxetine, enhancing patient access and adherence for the treatment of depression and anxiety disorders. This contributes to better overall mental health outcomes and can reduce long-term healthcare costs. For instance, in May 2024, the UK’s Office for National Statistics reported that healthcare expenditure in the country reached approximately $385 billion (£292 billion) in 2023, up from $373 billion (£283 billion) in 2022. Therefore, increasing healthcare expenditure is supporting the growth of the fluoxetine market.
Key companies in the fluoxetine market are focusing on innovative product developments, such as fluoxetine tablets, to treat various mental health conditions, including major depressive disorder. Fluoxetine tablets contain fluoxetine hydrochloride, an antidepressant classified as a selective serotonin reuptake inhibitor (SSRI). For example, in April 2024, Strides Pharma Global Pte. Limited, a Singapore-based pharmaceutical company, received United States FDA approval for Fluoxetine Tabs 10 mg and 20 mg. This approval expands the company’s fluoxetine portfolio by adding tablets alongside existing capsules. Fluoxetine, as an SSRI, is used to treat conditions such as major depressive disorder (MDD), obsessive-compulsive disorder (OCD), bulimia nervosa, and panic disorder with or without agoraphobia. Introducing fluoxetine tablets provides patients and healthcare providers with additional options and flexibility in managing these mental health disorders.
Major companies operating in the fluoxetine market are Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Hetero Ltd., Torrent Pharmaceuticals GmbH, Aurobindo Pharma, Cadila Pharmaceuticals Ltd., Dr. Reddy's Laboratories Limited, Apotex Inc., Amneal Pharmaceuticals Inc., Lupin Ltd., Glenmark Pharmaceuticals Inc., Alvogen, Alembic Pharmaceuticals Limited, Accord Healthcare Ltd., PERRIGO Company plc, Wockhardt Ltd., Jubilant Life Sciences Ltd., Lannett Company Inc., Mayne Pharma International Pty Ltd., Par Pharmaceutical Companies Inc., Zydus Pharmaceuticals USA Inc., Ascend Laboratories LLC.
North America was the largest region in the fluoxetine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fluoxetine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the fluoxetine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have affected the fluoxetine market by increasing costs for imported active pharmaceutical ingredients, excipients, and packaging materials. Hospital and retail pharmacies in Asia-Pacific and developing regions are most affected due to reliance on international pharmaceutical supply chains. These higher costs can raise antidepressant prices and limit patient access. However, tariffs are encouraging local API manufacturing and generic drug production, improving long-term affordability.
The fluoxetine market research report is one of a series of new reports that provides fluoxetine market statistics, including fluoxetine industry global market size, regional shares, competitors with a fluoxetine market share, detailed fluoxetine market segments, market trends and opportunities, and any further data you may need to thrive in the fluoxetine industry. This fluoxetine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) commonly prescribed as an antidepressant and for other psychiatric conditions. It works by increasing serotonin levels, a neurotransmitter that regulates mood, emotions, and behavior. Fluoxetine is widely used to treat depression, helping to improve sleep, appetite, and energy in individuals with major depressive disorder.
The main fluoxetine dosage forms include tablets, solutions, capsules, syrups, and others. Tablets are solid forms that dissolve in the stomach after ingestion. Fluoxetine can be administered orally and via other routes and is prescribed for adults, children, and the elderly. It is commonly used to treat conditions such as obsessive-compulsive disorder, panic disorder, depression, bulimia nervosa, and others, and is utilized by various end users including clinics, hospitals, and other healthcare facilities.
The fluoxetine market consists of sales of fluoxetine hydrochloride tablets, fluoxetine powder, and fluoxetine injection. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The fluoxetine market size is expected to see steady growth in the next few years. It will grow to $1.27 billion in 2030 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to growth in mental health treatment access, expansion of telepsychiatry services, rising stress-related disorders, increased use in pediatric and geriatric care, innovation in antidepressant therapy management. Major trends in the forecast period include rising use of SSRIs in mental health treatment, increased prescription for depression and anxiety disorders, growing adoption of generic fluoxetine, expansion of mental health awareness programs, preference for oral antidepressant therapies.
The rising prevalence of mental health disorders is expected to drive growth in the fluoxetine market. Mental health disorders include a wide range of conditions that impact cognitive, emotional, and behavioral functioning, often causing distress or impairments in daily life. Their increase is influenced by factors such as societal pressures, economic stress, lifestyle changes, and greater awareness and diagnosis. Fluoxetine is used to manage these disorders as it helps alleviate symptoms by increasing serotonin levels in the brain, a key neurotransmitter in mood regulation. For example, in August 2024, the Substance Abuse and Mental Health Services Administration (SAMHSA), a U.S.-based government agency, reported that nearly 25 percent of adults experienced any mental illness (AMI) in 2023, with about 17.1 percent meeting criteria for substance use disorder (SUD). Therefore, the rising prevalence of mental health disorders is boosting the fluoxetine market.
The growth in healthcare expenditure is also expected to support the expansion of the fluoxetine market. Rising healthcare costs are driven by factors such as the adoption of advanced medical technologies, aging populations, and the prevalence of chronic diseases. Higher healthcare spending improves the availability and affordability of medications like fluoxetine, enhancing patient access and adherence for the treatment of depression and anxiety disorders. This contributes to better overall mental health outcomes and can reduce long-term healthcare costs. For instance, in May 2024, the UK’s Office for National Statistics reported that healthcare expenditure in the country reached approximately $385 billion (£292 billion) in 2023, up from $373 billion (£283 billion) in 2022. Therefore, increasing healthcare expenditure is supporting the growth of the fluoxetine market.
Key companies in the fluoxetine market are focusing on innovative product developments, such as fluoxetine tablets, to treat various mental health conditions, including major depressive disorder. Fluoxetine tablets contain fluoxetine hydrochloride, an antidepressant classified as a selective serotonin reuptake inhibitor (SSRI). For example, in April 2024, Strides Pharma Global Pte. Limited, a Singapore-based pharmaceutical company, received United States FDA approval for Fluoxetine Tabs 10 mg and 20 mg. This approval expands the company’s fluoxetine portfolio by adding tablets alongside existing capsules. Fluoxetine, as an SSRI, is used to treat conditions such as major depressive disorder (MDD), obsessive-compulsive disorder (OCD), bulimia nervosa, and panic disorder with or without agoraphobia. Introducing fluoxetine tablets provides patients and healthcare providers with additional options and flexibility in managing these mental health disorders.
Major companies operating in the fluoxetine market are Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Hetero Ltd., Torrent Pharmaceuticals GmbH, Aurobindo Pharma, Cadila Pharmaceuticals Ltd., Dr. Reddy's Laboratories Limited, Apotex Inc., Amneal Pharmaceuticals Inc., Lupin Ltd., Glenmark Pharmaceuticals Inc., Alvogen, Alembic Pharmaceuticals Limited, Accord Healthcare Ltd., PERRIGO Company plc, Wockhardt Ltd., Jubilant Life Sciences Ltd., Lannett Company Inc., Mayne Pharma International Pty Ltd., Par Pharmaceutical Companies Inc., Zydus Pharmaceuticals USA Inc., Ascend Laboratories LLC.
North America was the largest region in the fluoxetine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fluoxetine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the fluoxetine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have affected the fluoxetine market by increasing costs for imported active pharmaceutical ingredients, excipients, and packaging materials. Hospital and retail pharmacies in Asia-Pacific and developing regions are most affected due to reliance on international pharmaceutical supply chains. These higher costs can raise antidepressant prices and limit patient access. However, tariffs are encouraging local API manufacturing and generic drug production, improving long-term affordability.
The fluoxetine market research report is one of a series of new reports that provides fluoxetine market statistics, including fluoxetine industry global market size, regional shares, competitors with a fluoxetine market share, detailed fluoxetine market segments, market trends and opportunities, and any further data you may need to thrive in the fluoxetine industry. This fluoxetine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) commonly prescribed as an antidepressant and for other psychiatric conditions. It works by increasing serotonin levels, a neurotransmitter that regulates mood, emotions, and behavior. Fluoxetine is widely used to treat depression, helping to improve sleep, appetite, and energy in individuals with major depressive disorder.
The main fluoxetine dosage forms include tablets, solutions, capsules, syrups, and others. Tablets are solid forms that dissolve in the stomach after ingestion. Fluoxetine can be administered orally and via other routes and is prescribed for adults, children, and the elderly. It is commonly used to treat conditions such as obsessive-compulsive disorder, panic disorder, depression, bulimia nervosa, and others, and is utilized by various end users including clinics, hospitals, and other healthcare facilities.
The fluoxetine market consists of sales of fluoxetine hydrochloride tablets, fluoxetine powder, and fluoxetine injection. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Fluoxetine Market Characteristics
3. Fluoxetine Market Supply Chain Analysis
4. Global Fluoxetine Market Trends and Strategies
5. Fluoxetine Market Analysis of End Use Industries
7. Global Fluoxetine Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Fluoxetine Total Addressable Market (TAM) Analysis for the Market
9. Fluoxetine Market Segmentation
10. Fluoxetine Market Regional and Country Analysis
11. Asia-Pacific Fluoxetine Market
12. China Fluoxetine Market
13. India Fluoxetine Market
14. Japan Fluoxetine Market
15. Australia Fluoxetine Market
16. Indonesia Fluoxetine Market
17. South Korea Fluoxetine Market
18. Taiwan Fluoxetine Market
19. South East Asia Fluoxetine Market
20. Western Europe Fluoxetine Market
21. UK Fluoxetine Market
22. Germany Fluoxetine Market
23. France Fluoxetine Market
24. Italy Fluoxetine Market
25. Spain Fluoxetine Market
26. Eastern Europe Fluoxetine Market
27. Russia Fluoxetine Market
28. North America Fluoxetine Market
29. USA Fluoxetine Market
30. Canada Fluoxetine Market
31. South America Fluoxetine Market
32. Brazil Fluoxetine Market
33. Middle East Fluoxetine Market
34. Africa Fluoxetine Market
36. Fluoxetine Market Competitive Landscape and Company Profiles
37. Fluoxetine Market Other Major and Innovative Companies
40. Fluoxetine Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Fluoxetine Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses fluoxetine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for fluoxetine? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The fluoxetine market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Dosage Form: Tablet; Capsule; Other Dosage Forms2) By Route Of Administration: Oral; Other Routes Of Administration
3) By Demographic: Adult; Pediatric; Geriatric
4) By Application: Obsessive-Compulsive Disorder; Panic Disorder; Depression; Bulimia Nervosa; Other Applications
5) By End User: Clinic; Hospital; Other End Users
Subsegments:
1) By Tablet: Regular Tablets; Extended-Release Tablets2) By Capsule: Standard Capsules; Delayed-Release Capsules
3) By Other Dosage Forms: Injection Form; Topical Form
Companies Mentioned: Eli Lilly and Company; Viatris Inc.; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd.; Hetero Ltd.; Torrent Pharmaceuticals GmbH; Aurobindo Pharma; Cadila Pharmaceuticals Ltd.; Dr. Reddy's Laboratories Limited; Apotex Inc.; Amneal Pharmaceuticals Inc.; Lupin Ltd.; Glenmark Pharmaceuticals Inc.; Alvogen; Alembic Pharmaceuticals Limited; Accord Healthcare Ltd.; PERRIGO Company plc; Wockhardt Ltd.; Jubilant Life Sciences Ltd.; Lannett Company Inc.; Mayne Pharma International Pty Ltd.; Par Pharmaceutical Companies Inc.; Zydus Pharmaceuticals USA Inc.; Ascend Laboratories LLC
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Fluoxetine market report include:- Eli Lilly and Company
- Viatris Inc.
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Hetero Ltd.
- Torrent Pharmaceuticals GmbH
- Aurobindo Pharma
- Cadila Pharmaceuticals Ltd.
- Dr. Reddy's Laboratories Limited
- Apotex Inc.
- Amneal Pharmaceuticals Inc.
- Lupin Ltd.
- Glenmark Pharmaceuticals Inc.
- Alvogen
- Alembic Pharmaceuticals Limited
- Accord Healthcare Ltd.
- PERRIGO Company plc
- Wockhardt Ltd.
- Jubilant Life Sciences Ltd.
- Lannett Company Inc.
- Mayne Pharma International Pty Ltd.
- Par Pharmaceutical Companies Inc.
- Zydus Pharmaceuticals USA Inc.
- Ascend Laboratories LLC
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 1.08 Billion |
| Forecasted Market Value ( USD | $ 1.27 Billion |
| Compound Annual Growth Rate | 4.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
